Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Diabetes has become important risk factors for threatening human life and health. Lower extremity arterial occlusive are the common complications of diabetes.Sulfur amino acid is the indispensable amino acid in mammals, and its metabolites include Taurine, Hydrogen sulfide (H2S) and sulfur dioxide (SO2). Taurine was first isolated more than 150 years ago from ox (Taurus) bile. Although the taurine can be synthesized in vivo by cysteine in the presence of cysteine dioxygenase, it is mainly acquired from dietary sources, such as eggs, meat, and seafood. H2S is a biologically relevant mediator and plays potential roles in several physiological processes and disease states in the body. H2S is synthesized from 2 sulfur-containing amino acids, l-cysteine andl-methionine, by the 3 enzymes,cystathionine-γ-lyase (CSE), cystathionine-β-synthetase(CBS), and3-mercaptopyruvate sulfurtransferase (3-MST). Previous studies have demonstrated that Taurine and H2S may play important roles in the development of the microangiopathy and lower extremity arterial occlusive.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Taurine Supplementation | Experimental | Taurine 2.4mg/d for 12 weeks |
|
| Placebo | Placebo Comparator | Placebo 2.4mg/d for 12 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Taurine | Drug |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Ankle-brachial index | Changes of ankle-brachial index after 12 weeks. | Baseline, 12weeks(End of Trial) |
| Measure | Description | Time Frame |
|---|---|---|
| 24-hours mean blood pressure. | Baseline, 12weeks(End of Trial) | |
| Pulse wave velocity(PWV) | Baseline, 12weeks(End of Trial) | |
| Fasting plasma glucose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yan Zhencheng, MD | Contact | 86-023-68757882 | zhenchengyan@sina.com | |
| Zhu Zhiming, MD | Contact | 86-23-68767881 | zhuzm@yahoo.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The third hospital affiliated to the Third Military Medical University | Recruiting | Chongqing | Chongqing Municipality | 400042 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D013654 | Taurine |
| ID | Term |
|---|---|
| D017738 | Alkanesulfonic Acids |
| D000473 | Alkanes |
| D006839 | Hydrocarbons, Acyclic |
| D006838 | Hydrocarbons |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Baseline, 12weeks(End of Trial) |
| HbA1c | Baseline, 12weeks(End of Trial) |
| Lipid profile (triglyceride, total cholesterol, LDL-c; HDL-c; mmol/L) | Baseline, 12weeks(End of Trial) |
| Carotid intima-media thickness(IMT) | Baseline, 12weeks(End of Trial) |
| Body mass index(BMI) | Baseline, 12weeks(End of Trial) |
| Fasting serum insulin | Baseline, 12weeks(End of Trial) |
| D009930 |
| Organic Chemicals |
| D013451 | Sulfonic Acids |
| D013456 | Sulfur Acids |
| D013457 | Sulfur Compounds |